JP2012509929A - 多型 - Google Patents

多型 Download PDF

Info

Publication number
JP2012509929A
JP2012509929A JP2011538053A JP2011538053A JP2012509929A JP 2012509929 A JP2012509929 A JP 2012509929A JP 2011538053 A JP2011538053 A JP 2011538053A JP 2011538053 A JP2011538053 A JP 2011538053A JP 2012509929 A JP2012509929 A JP 2012509929A
Authority
JP
Japan
Prior art keywords
vorinostat
crystal
type
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011538053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509929A5 (enExample
Inventor
ゴレ，ビナーヤク
パティル，マドゥカル
ブハレラオ，ラフール
マンデ，ヘマント
Original Assignee
ジェネリクス・（ユーケー）・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネリクス・（ユーケー）・リミテッド filed Critical ジェネリクス・（ユーケー）・リミテッド
Publication of JP2012509929A publication Critical patent/JP2012509929A/ja
Publication of JP2012509929A5 publication Critical patent/JP2012509929A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011538053A 2008-11-26 2009-11-25 多型 Pending JP2012509929A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2057KO2008 2008-11-26
IN2057/KOL/2008 2008-11-26
PCT/GB2009/051596 WO2010061219A2 (en) 2008-11-26 2009-11-25 Polymorphs

Publications (2)

Publication Number Publication Date
JP2012509929A true JP2012509929A (ja) 2012-04-26
JP2012509929A5 JP2012509929A5 (enExample) 2013-01-17

Family

ID=42226168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011538053A Pending JP2012509929A (ja) 2008-11-26 2009-11-25 多型

Country Status (8)

Country Link
US (1) US8754129B2 (enExample)
EP (1) EP2362869A2 (enExample)
JP (1) JP2012509929A (enExample)
CN (1) CN102282126A (enExample)
AU (1) AU2009321384A1 (enExample)
CA (1) CA2744448A1 (enExample)
NZ (1) NZ593585A (enExample)
WO (1) WO2010061219A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2349985A2 (en) 2008-10-15 2011-08-03 Generics [UK] Limited Process for the preparation of vorinostat
CN110283102B (zh) * 2019-05-31 2022-09-27 宿州亿帆药业有限公司 一种伏林司他ⅰ晶型的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039421A2 (en) * 2006-09-28 2008-04-03 Merck & Co., Inc. Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
WO2008042146A1 (en) * 2006-09-28 2008-04-10 Merck & Co., Inc. Amine base salts of saha and polymorphs thereof
JP2008519081A (ja) * 2005-05-20 2008-06-05 メルク エンド カムパニー インコーポレーテッド スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9504084D0 (en) 1995-03-01 1995-04-19 British Biotech Pharm Synthesis of carboxylic and hydroxamic acid derivatives
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6497820B1 (en) 1998-02-03 2002-12-24 Arqule, Inc. Rapid method for separation of small molecules using reverse phase high performance liquid chromatography
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
NZ550185A (en) 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
EP1663194B1 (en) 2003-08-26 2010-03-31 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
EP1541549A1 (en) 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
UA93355C2 (ru) * 2005-05-20 2011-02-10 Mepk Шарп Энд Доме Корп. Композиция субероиланилид-гидроксаминовой кислоты и способы ee получения
AU2008337304A1 (en) 2007-12-14 2009-06-25 Generics [Uk] Limited HPLC method for analysing clopidogrel
JP2011511053A (ja) 2008-02-07 2011-04-07 ジェネリクス・（ユーケー）・リミテッド ボリノスタットの新規な製造方法
US20090223286A1 (en) 2008-02-13 2009-09-10 Vandana Singh Analytical method for determination of related substances of imipenem and cilastatin
CZ2008167A3 (cs) 2008-03-14 2010-02-24 Zentiva, A. S. Specifické necistoty montelukastu
EP2349985A2 (en) 2008-10-15 2011-08-03 Generics [UK] Limited Process for the preparation of vorinostat
CA2744458A1 (en) 2008-11-26 2010-06-03 Generics [Uk] Limited Novel processes and pure polymorphs
WO2011061545A1 (en) 2009-11-23 2011-05-26 Generics [Uk] Limited Hplc method for analyzing vorinostat

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519081A (ja) * 2005-05-20 2008-06-05 メルク エンド カムパニー インコーポレーテッド スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法
WO2008039421A2 (en) * 2006-09-28 2008-04-03 Merck & Co., Inc. Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
WO2008042146A1 (en) * 2006-09-28 2008-04-10 Merck & Co., Inc. Amine base salts of saha and polymorphs thereof

Also Published As

Publication number Publication date
NZ593585A (en) 2012-12-21
US8754129B2 (en) 2014-06-17
US20110263713A1 (en) 2011-10-27
CN102282126A (zh) 2011-12-14
WO2010061219A2 (en) 2010-06-03
EP2362869A2 (en) 2011-09-07
CA2744448A1 (en) 2010-06-03
WO2010061219A3 (en) 2010-08-12
AU2009321384A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
ES2562843T3 (es) Forma IV de clorhidrato de ivabradina
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
JP2011503185A (ja) ヘミフマル酸アリスキレンの多形形態及びその調製プロセス
CN1812968B (zh) 4-[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯硫基)丙基]-2-丙基苯氧基]丁酸的多晶型物
JP2012509930A (ja) 新規な方法および純粋な多型
EA020545B1 (ru) Соли карбоновой кислоты 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
US8754129B2 (en) Crystalline vorinostat form VI
JP2020524707A (ja) 塩酸メフパリブの多形体およびその製造方法と使用
TWI333856B (en) Crystals of taxane and process for their production
TWI708764B (zh) 一種雄性激素受體抑制劑的結晶形式及其製備方法
CN1880294B (zh) 右酮洛芬氨丁三醇的多晶型、其制备方法和包含它的组合物
CN106478616B (zh) 一种gpr40激动剂的结晶形式及其制备方法
WO2019099761A1 (en) Solid state forms of elafibranor
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
WO2001068587A1 (en) Novel crystal of stilbene derivative and process for producing the same
CN102219752B (zh) 一种1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的晶型d
EP1751148A1 (en) Ziprasidone hydrochloride polymorph and process for its preparation
WO2011028919A2 (en) Solid forms of aliskiren hemifumarate and processes for preparation thereof
CA2657117A1 (en) Crystals of benzoxadiazole derivative
EP1785411A1 (en) Protriptyline hydrochloride crystalline form

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140805